RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
about
Acute Myeloid Leukemia: A Concise ReviewGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaPost-remission therapy for acute myeloid leukemiaCIViC databaseRUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.Novel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaTargeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentRUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case reportSignificance of oncogenes and tumor suppressor genes in AML prognosis.Runx1 and Cbfβ regulate the development of Flt3+ dendritic cell progenitors and restrict myeloproliferative disorder.GAS6 expression identifies high-risk adult AML patients: potential implications for therapyDifferential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AMLMolecular therapy for acute myeloid leukaemia.ASXL genes and RUNX1: an intimate connection?Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.An integrated approach of gene expression and DNA-methylation profiles of WNT signaling genes uncovers novel prognostic markers in acute myeloid leukemia.ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaIntegrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemiaPrognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis.Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid LeukemiaMitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.The Globalization of Cooperative Groups.Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia.An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype.UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.The benefit of population-based studies for older patients with acute myeloid leukemiaClinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsHigh expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.MicroRNA-205 downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic leukemia.CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcomeA stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigationsRUNX1: A microRNA hub in normal and malignant hematopoiesis.
P2860
Q26766719-E4008CB8-A333-4CD0-98A7-FC998A46AA47Q26796514-FB8E49BE-7B36-44E3-BE6A-0B9D6249B93AQ26995867-E62B0B14-0EF6-4667-9E57-C16888F2DBD4Q27612411-846D725B-4D7E-487A-9D59-9585689FA266Q27853381-ACA2881C-EDAE-442B-9C22-CCCB0623A075Q28075654-957E731C-992F-47B9-8A4E-4A856B0525DBQ28076462-D264A269-235E-45FC-B338-8A51DF29CDDCQ28597831-4F327A7F-17B2-41DE-9CEA-15C007AE08EAQ30250315-1C7373C9-68E9-42AB-A348-65DC649560C8Q33585261-C3ADB3EB-E520-428A-901E-7AD2F59F2E1DQ33717707-A96C5CDA-686C-4722-B615-BBD1DB09CB00Q33868160-DF728108-FA49-4C98-A34B-75DA9BADBEFEQ33925672-54591EF8-ADE3-4870-A94A-CF2CB735EF75Q34106779-908F57C4-A602-4760-A061-3537D3A3F201Q34663691-8FA78DFE-AFA2-4664-B1C6-E728D85BCF13Q34831106-1033CE4D-6C11-4838-A575-70737B07B5CFQ35141163-00A66967-03BA-425D-A98C-216148BE284AQ35146279-C8406B22-A049-455D-8784-C4959F1FCCE2Q35152173-6C66F3F4-30F0-4A48-A4CC-733E809E9247Q35562821-58457BDF-79F2-4F6E-81E8-CBC56C2FFE4BQ35617980-D138D755-E49C-44C8-8DDF-A9F2E928CBC2Q35692708-2F41F47E-8568-40EF-AEA5-5215230337DAQ35781530-568A63DB-6063-4A40-B213-8A51CB11623AQ36119749-D6ADDD40-5A3B-4B7F-8416-91E8730DE6F2Q36457184-995A016D-233E-47AB-B943-26D714ACF265Q36529502-6BCD199E-0428-4348-97DD-06B656D1E664Q36585150-BAD91BE1-8D44-4EED-B4AE-B6267EB1952EQ36629521-A6B227AE-65B5-4754-A063-3D5D9E86DC69Q36642902-B74D4765-DD48-44F8-975D-2DC03B6F7D0EQ36662009-66C6379E-BF5A-4452-AF95-075F0023D5D8Q37065843-D89146CA-2EF0-4A37-B04D-D4D72C5C0486Q37085891-4FD1AFFF-F116-4410-9516-11D5A65D4BD9Q37146560-C4F79E76-FA06-4F54-B194-EC4ACD8474C1Q37327786-34BE6F15-8FCE-4F91-8F7F-350BCC6613FDQ37474559-1F0CB5B4-0248-40E5-9AB1-3A41882B9313Q37570427-1455926D-763C-4F0B-93A4-0026BAC52C18Q37624593-A1B1651C-B945-4211-B155-AC21127100D9Q37648114-0FE48968-CF5A-4A31-803B-95538EFC84AEQ37652896-99EBC7DD-3CD7-4FBA-B9E2-DDB28E36F67CQ38076281-F95B2CE1-9550-4DC0-AB81-556F7D3E2AE8
P2860
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
RUNX1 mutations are associated ...... icroRNA expression signatures.
@ast
RUNX1 mutations are associated ...... icroRNA expression signatures.
@en
RUNX1 mutations are associated ...... icroRNA expression signatures.
@nl
type
label
RUNX1 mutations are associated ...... icroRNA expression signatures.
@ast
RUNX1 mutations are associated ...... icroRNA expression signatures.
@en
RUNX1 mutations are associated ...... icroRNA expression signatures.
@nl
altLabel
RUNX1 Mutations Are Associated ...... MicroRNA Expression Signatures
@en
prefLabel
RUNX1 mutations are associated ...... icroRNA expression signatures.
@ast
RUNX1 mutations are associated ...... icroRNA expression signatures.
@en
RUNX1 mutations are associated ...... icroRNA expression signatures.
@nl
P2093
P2860
P50
P921
P3181
P356
P1476
RUNX1 mutations are associated ...... icroRNA expression signatures.
@en
P2093
Andrew J Carroll
Bayard L Powell
Deedra Nicolet
Heiko Becker
Jihane Khalife
Jonathan E Kolitz
Joseph O Moore
Maria R Baer
Meir Wetzler
Michael A Caligiuri
P2860
P304
P3181
P356
10.1200/JCO.2011.40.6652
P407
P50
P577
2012-09-01T00:00:00Z